John Anderson

Summary

Country: UK

Publications

  1. ncbi The role of antiandrogen monotherapy in the treatment of prostate cancer
    J Anderson
    Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 91:455-61. 2003
  2. pmc The case for radical prostatectomy
    John Anderson
    Sheffield Teaching Hospitals, UK
    Ann R Coll Surg Engl 87:159-60. 2005
  3. pmc Controversial topics in surgery. Radical prostatectomy
    John Anderson
    Sheffield Teaching Hospitals, Sheffield, UK
    Ann R Coll Surg Engl 87:159-62. 2005
  4. ncbi Chemotherapy for older patients with prostate cancer
    John Anderson
    Department of Urology, University Hospital KU Leuven, Belgium
    BJU Int 99:269-73. 2007
  5. ncbi Uneventful administration of vincristine in Charcot-Marie-Tooth disease type 1X
    Richa Ajitsaria
    Department of Paediatric Oncology, Great Ormond Street Hospital, London, UK
    Pediatr Blood Cancer 50:874-6. 2008
  6. pmc Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
    Matthew R Sydes
    MRC Clinical Trials Unit, London, UK
    Trials 13:168. 2012
  7. doi Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer
    John Anderson
    Department of Urology, Royal Hallamshire Hospital, Glossop Road, Sheffield, UK
    Future Oncol 5:433-43. 2009
  8. doi Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
    John Anderson
    Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 101:1497-501. 2008
  9. doi Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233)
    John Anderson
    Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
    Urol Int 90:321-8. 2013
  10. ncbi Bicalutamide 150 mg: practical prescribing in patients with early prostate cancer
    John Anderson
    Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 94:758-9. 2004

Collaborators

Detail Information

Publications18

  1. ncbi The role of antiandrogen monotherapy in the treatment of prostate cancer
    J Anderson
    Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 91:455-61. 2003
    ..Bicalutamide has a more favourable side-effect profile than the other antiandrogens and is more likely to promote compliance...
  2. pmc The case for radical prostatectomy
    John Anderson
    Sheffield Teaching Hospitals, UK
    Ann R Coll Surg Engl 87:159-60. 2005
  3. pmc Controversial topics in surgery. Radical prostatectomy
    John Anderson
    Sheffield Teaching Hospitals, Sheffield, UK
    Ann R Coll Surg Engl 87:159-62. 2005
  4. ncbi Chemotherapy for older patients with prostate cancer
    John Anderson
    Department of Urology, University Hospital KU Leuven, Belgium
    BJU Int 99:269-73. 2007
  5. ncbi Uneventful administration of vincristine in Charcot-Marie-Tooth disease type 1X
    Richa Ajitsaria
    Department of Paediatric Oncology, Great Ormond Street Hospital, London, UK
    Pediatr Blood Cancer 50:874-6. 2008
    ..CMT should be excluded in any patient who develops a profound, acute neuropathy following vincristine, as many patients in the cases reviewed were asymptomatic prior to treatment...
  6. pmc Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
    Matthew R Sydes
    MRC Clinical Trials Unit, London, UK
    Trials 13:168. 2012
    ..We describe methodological and practical issues arising with (1) stopping recruitment to research arms following a pre-planned intermediate analysis and (2) adding a new research arm during the trial...
  7. doi Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer
    John Anderson
    Department of Urology, Royal Hallamshire Hospital, Glossop Road, Sheffield, UK
    Future Oncol 5:433-43. 2009
    ..Degarelix was well tolerated; the most common side effects were mild/moderate injection-site reactions and hot flashes. Findings to date suggest that degarelix may make an important contribution to the treatment of prostate cancer...
  8. doi Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
    John Anderson
    Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 101:1497-501. 2008
    ..Preliminary data for the GnRH blocker, degarelix, suggest that this new agent might overcome the shortcomings associated with GnRH agonists. Further clinical data are therefore awaited with much interest...
  9. doi Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233)
    John Anderson
    Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
    Urol Int 90:321-8. 2013
    ..No studies to date have assessed the efficacy/tolerability of degarelix in the relief of lower urinary tract symptoms (LUTS) secondary to prostate cancer (PrCa)...
  10. ncbi Bicalutamide 150 mg: practical prescribing in patients with early prostate cancer
    John Anderson
    Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
    BJU Int 94:758-9. 2004
  11. doi Adapting treatment for prostate cancer according to risk of disease progression
    John Anderson
    Royal Hallamshire Hospital, Sheffield, UK
    Crit Rev Oncol Hematol 68:S23-31. 2008
    ..This article discusses current treatment options for localized and advanced prostate cancer, with a focus on how treatment can be optimized through consideration of a patient's risk of disease progression...
  12. pmc Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study
    J W F Catto
    Academic Urology Unit and Institute for Cancer Studies, University of Sheffield, Sheffield, UK
    Br J Cancer 105:931-7. 2011
    ..To identify which patients might benefit from focal ablative techniques, we analysed the surgical specimens of a large sample of population-detected men undergoing radical prostatectomy as part of a randomised clinical trial...
  13. ncbi Quality of life aspects of treatment options for localized and locally advanced prostate cancer
    J Anderson
    Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
    Eur Urol 40:24-30. 2001
    ..The risk of treatment-related side effects or influence on the total quality of life must be considered carefully for each individual patient in order to assess the most appropriate treatment option...
  14. ncbi Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration
    Chris J Tyrrell
    Derriford Hospital, Plymouth, UK
    BJU Int 98:563-72. 2006
    ....
  15. ncbi MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma
    Daniel A Morgenstern
    Northwick Park Hospital, Harrow, HA1 3UJ, UK
    Expert Rev Anticancer Ther 6:217-24. 2006
    ..A range of possible approaches to target MYCN is discussed, including nucleic acid-based and immunotherapy strategies...
  16. doi Androgen-deprivation therapy-it's all a matter of timing
    John Anderson
    Eur Urol 53:869-71. 2008
  17. ncbi Physician and patient based outcomes following surgical resection of Haglund's deformity
    John Brunner
    Hospital for Special Surgery, Department of Foot and Ankle Surgery, New York, NY, 10021, USA
    Acta Orthop Belg 71:718-23. 2005
    ..However, patients must be made aware of the necessary time to recovery, between 6 months and 2 years...
  18. ncbi The loss rates for invasive prenatal testing in a specialised obstetric ultrasound practice
    Fergus Scott
    Sydney Ultrasound for Women, New South Wales, Australia
    Aust N Z J Obstet Gynaecol 42:55-8. 2002
    ..To establish the spontaneous miscarriage rate and compare it with the procedure related miscarriage rate for amniocentesis and chorionic villus sampling (CVS) by experienced operators...